The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.
Calprotectin – The 1st Line Lab for Helping Diagnose IBD
Free Test Summary from Quest
Inflammatory bowel disease (IBD) is characterized by chronic, relapsing inflammation of the gastrointestinal (GI) tract lining. The two primary forms of IBD are Crohn's disease and ulcerative colitis, which share clinical symptoms such as abdominal pain, dyspepsia, and diarrhea that can be profuse and bloody. Abdominal pain, dyspepsia, and diarrhea (non-bloody) are also seen in patients with IBS. Distinguishing IBD, an organic disease, from IBS, a functional disease, is important, as treatments are vastly different. Diagnosis is typically based on history and examination, laboratory testing, imaging studies, and colonoscopy/endoscopy and histological findings. Though colonoscopy is the gold standard for diagnosing IBD, routine use is not warranted as it is costly, invasive, and associated with low-but-measurable morbidity.
Calprotectin is a small calcium-binding protein that makes up about 60% of neutrophil cytosol protein content. During inflammation, neutrophils migrate to the intestinal mucosa, and calprotectin is leaked into the bowel lumen. Numerous studies have shown that stool calprotectin concentration can help diagnose IBD, and distinguish it from IBS and other conditions with a similar presentation. In a 2010 meta-analysis, elevated stool calprotectin demonstrated a sensitivity of 93% and a specificity of 96% for differentiating IBD from other causes of GI symptoms in adults. In children and teenagers, the sensitivity is 92% and the specificity is 76%. Calprotectin may be used as one of the initial tests in patients with suspected IBD; levels can help avoid unnecessary colonoscopy, as normal levels are not typically associated with active IBD. Conversely, levels above normal are consistent with organic diseases such as IBD and colorectal cancer, and warrant consideration of colonoscopy.
Calprotectin testing can also be used to monitor response to IBD treatment, since lower concentrations correlate with less severe disease and better response to treatment. The correlation, however, is higher in patients with colonic than ileal disease activity. Failure of calprotectin level to normalize with treatment is considered an indication for further endoscopic evaluation, regardless of symptoms.
Among IBD patients who are in remission, calprotectin helps predict those who will experience a relapse. Gisbert et al showed that an elevated calprotectin concentration predicted relapse during the next 12 months with a sensitivity of 69% and a specificity of 75%. Costa et al showed that Crohn's disease patients in remission had a two-fold, and ulcerative colitis patients a 14-fold, increased risk of relapse when the stool calprotectin concentration was elevated. Another study showed that Crohn's disease patients with an elevated calprotectin concentration during remission had an 18- fold higher risk of relapse. Calprotectin concentration may also be useful for predicting relapse of Crohn's disease after surgical resection. A rapid decrease of calprotectin concentration after induction therapy has been shown to predict remission.
A concentration within the reference range indicates a very low likelihood (<95%) of bowel inflammation. A concentration above the reference range is consistent with inflammation of the bowel; the concentration increases as the degree of inflammation increases. An elevated calprotectin concentration is consistent with, but not diagnostic of, IBD. A diagnosis of IBD cannot be established based solely on an increased calprotectin concentration. Other conditions as diverse as colon cancer, diverticular disease, and liver cirrhosis, as well as nonsteroidal anti-inflammatory drugs (NSAIDs) or recent infectious enteritis, can result in an elevated concentration.